Holen Sie sich die Stockscreener-App
18.80
1.62%
0.30
Handel nachbörslich:
18.80
Schlusskurs vom Vortag:
$18.50
Offen:
$18.17
24-Stunden-Volumen:
81,112
Relative Volume:
0.67
Marktkapitalisierung:
$164.59M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-940.00
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
-1.00%
1M Leistung:
+27.20%
6M Leistung:
+40.28%
1J Leistung:
+14.68%
1-Tages-Spanne:
$17.82
$19.04
1-Wochen-Bereich:
$17.82
$19.87
52-Wochen-Spanne:
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
18.80 | 170.89M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Is Seres Therapeutics Inc. affected by consumer sentimentTrend Reversal & Weekly High Return Stock Opportunities - khodrobank.com
Is now a turning point for Seres Therapeutics Inc.Market Movers & Growth Focused Stock Pick Reports - Newser
Ranking Seres Therapeutics Inc. among high performing stocks via tools2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
How to read the order book for Seres Therapeutics Inc.Exit Point & Smart Investment Allocation Insights - Newser
What machine learning models say about Seres Therapeutics Inc.July 2025 Breakouts & Technical Buy Zone Confirmations - Newser
What MACD signals say about Seres Therapeutics Inc.Gold Moves & Long-Term Growth Portfolio Plans - Newser
Using Bollinger Bands to evaluate Seres Therapeutics Inc.2025 Stock Rankings & Safe Entry Trade Reports - Newser
Is Seres Therapeutics Inc. still worth holding after the dipDividend Hike & Stepwise Swing Trade Plans - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strength2025 Support & Resistance & Stock Market Timing Techniques - Newser
Seres Therapeutics Inc. stock outlook for YEARJuly 2025 Opening Moves & Reliable Trade Execution Plans - Newser
Evaluating Seres Therapeutics Inc. with trendline analysisWeekly Profit Recap & Free Long-Term Investment Growth Plans - Newser
Top chart patterns to watch in Seres Therapeutics Inc.July 2025 Review & Weekly Watchlist for Consistent Profits - Newser
What is Seres Therapeutics Inc. s debt to equity ratioQuarterly Earnings Summary & Weekly Hot Stock Watchlists - khodrobank.com
Tick level data insight on Seres Therapeutics Inc. volatilityJuly 2025 Review & Risk Controlled Stock Alerts - Newser
What moving averages say about Seres Therapeutics Inc.July 2025 Market Mood & AI Forecasted Stock Moves - Newser
Visual analytics tools that track Seres Therapeutics Inc. performanceMarket Movement Recap & Technical Confirmation Alerts - Newser
Is Seres Therapeutics Inc. backed by strong institutional buyingTrade Analysis Report & Target Return Focused Picks - khodrobank.com
Has Seres Therapeutics Inc. formed a bullish divergenceJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Volume spikes in Seres Therapeutics Inc. stock – what they mean2025 Sector Review & Safe Entry Point Alerts - Newser
Pattern recognition hints at Seres Therapeutics Inc. upsideQuarterly Growth Report & Low Drawdown Trading Strategies - Newser
Can Seres Therapeutics Inc. be the next market leaderMarket Trend Summary & High Conviction Buy Zone Picks - khodrobank.com
Applying chart zones and confluence areas to Seres Therapeutics Inc.Weekly Volume Report & Real-Time Volume Analysis Alerts - Newser
What candlestick patterns are forming on Seres Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser
Why Seres Therapeutics Inc. stock attracts strong analyst attention2025 Fundamental Recap & Weekly High Momentum Picks - Newser
Is Seres Therapeutics Inc. subject to activist investor interestWeekly Trade Review & Detailed Earnings Play Strategies - khodrobank.com
Seres Therapeutics Inc. stock volume spike explained2025 Volatility Report & Low Drawdown Momentum Trade Ideas - Newser
Earnings visualization tools for Seres Therapeutics Inc.2025 Trading Recap & Daily Stock Trend Reports - Newser
Full technical analysis of Seres Therapeutics Inc. stockQuarterly Trade Review & Daily Growth Stock Investment Tips - Newser
Is Seres Therapeutics Inc. Starting a New UptrendQuarterly Portfolio Report & Free High Return Stock Watch Alerts - beatles.ru
Custom strategy builders for tracking Seres Therapeutics Inc.Quarterly Profit Summary & Daily Volume Surge Signals - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis toolsWeekly Market Outlook & Entry Point Confirmation Signals - Newser
Advanced analytics toolkit walkthrough for Seres Therapeutics Inc.July 2025 Rallies & AI Driven Stock Reports - Newser
Custom watchlist performance reports with Seres Therapeutics Inc.Take Profit & Reliable Price Action Trade Plans - Newser
Published on: 2025-08-31 12:42:02 - Newser
Order flow analysis tools used on Seres Therapeutics Inc.2025 Earnings Impact & Low Volatility Stock Recommendations - Newser
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seres Therapeutics Inc-Aktie (MCRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DesRosier Thomas | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
76 |
1,265 |
7,455 |
| Henn Matthew R | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
73 |
1,215 |
4,548 |
| Young Teresa L. | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
59 |
982 |
5,215 |
| Young Teresa L. | See Remarks |
May 16 '25 |
Sale |
7.28 |
63 |
459 |
5,044 |
| Shaff Eric D. | CEO and President |
May 16 '25 |
Sale |
7.28 |
220 |
1,602 |
10,102 |
| DesRosier Thomas | Chief Legal Officer and EVP |
May 15 '25 |
Sale |
7.28 |
79 |
575 |
7,287 |
| Henn Matthew R | See Remarks |
May 16 '25 |
Sale |
7.28 |
77 |
561 |
4,383 |
| Young Teresa L. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,338 |
2,704 |
97,536 |
| Henn Matthew R. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,953 |
3,204 |
84,443 |
| Shaff Eric D. | CEO and President |
Feb 18 '25 |
Sale |
0.81 |
12,726 |
10,314 |
192,039 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):